State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.
Aims, results, advantages and possible disadvantages of preoperative chemotherapy (pCHT) for breast cancer are discussed in this review. Established chemotherapeutic regimens are described with respect to new drugs that are added to combinations now and in the future. Illustrating the potential of new components, trastuzumab and cytotoxic chemotherapy, were combined in neoadjuvant trials for the first time. This approach yielded impressing and unprecedented high pathological response rates. An overview regarding current neoadjuvant cytostatic and immunotherapy trials is given. Established prognostic factors like axillary lymph-nodal status are altered during pCHT, which causes the need for new prognostic markers. The consequences of these changes for clinical decision making are demonstrated. It seems possible that the advances of gene array and protein expression profile technologies will lead to improved prognostic and predictive statements. Tumor tissue can be analyzed before during and after treatment in this regard recent studies investigating the response to specific, chemotherapeutics in correlation to molecular markers are reviewed. These approaches might enable us to identify chemoresistance of specific tumors. Furthermore pCHT allows testing of chemosensitivity in vivo in an early stage, which might lead to a more individualized cancer therapy. We discuss radiotherapy after neoadjuvant therapy and the risk of local relapse after breast conserving surgery, which was made feasible by pCHT. It is shown how the evaluation of efficacy of new cancer drugs, using the neoadjuvant situation, can be done more rapidly than in the metastatic and adjuvant setting.
Honig
Arnd
A
Department of Obstetrics and Gynecology, University of Würzburg, Würzburg, Germany. Arnd_Hoenig@hotmail.com
Rieger
Lorenz
L
Sutterlin
Marc
M
Wallwiener
Diethelm
D
Dietl
Johannes
J
Solomayer
Erich-Franz
EF
Clin Breast Cancer. 2002 May;3 Suppl 1:39-44
12057045
Gynakol Geburtshilfliche Rundsch. 2004 Apr;44(2):92-101
15073438
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Breast Cancer Res Treat. 1999 Nov;58(2):151-6
10674880
Ann Surg. 1995 Nov;222(5):612-8
7487207
Clin Cancer Res. 1997 Apr;3(4):593-600
9815725
Cancer Res. 1979 Oct;39(10):3861-5
476622
Cancer Res. 1989 Apr 15;49(8):1996-2001
2702641
Arch Surg. 1989 Jan;124(1):21-5
2910244
Cancer. 2001 Sep 1;92(5):1080-4
11571718
Eur J Cancer. 2004 Nov;40(16):2432-8
15519516
Anticancer Res. 2000 Nov-Dec;20(6B):4373-7
11205274
Cancer J. 2001 Sep-Oct;7(5):413-20
11693900
Lancet. 2003 Aug 2;362(9381):362-9
12907009
Cancer Res. 2001 Mar 15;61(6):2505-12
11289122
Cancer Invest. 2004;22(2):248-56
15199607
J Clin Oncol. 2002 Jan 1;20(1):17-23
11773149
N Engl J Med. 1976 Feb 19;294(8):405-10
1246307
Endocr Relat Cancer. 2002 Sep;9(3):183-95
12237246
J Clin Oncol. 1999 Feb;17(2):460-9
10080586
Cancer Res. 2001 Mar 1;61(5):2207-11
11280788
J Clin Oncol. 1999 Oct;17(10):3058-63
10506600
Ann Oncol. 2004 Sep;15(9):1352-7
15319241
Clin Breast Cancer. 2002 Oct;3(4):276-80
12425756
J Clin Oncol. 2005 Apr 20;23(12):2694-702
15837984
Anticancer Drugs. 2004 Feb;15(2):127-35
15075668
J Clin Oncol. 1997 Jul;15(7):2483-93
9215816
Nature. 2002 Jan 31;415(6871):530-6
11823860
Am J Clin Oncol. 2002 Jun;25(3):303-7
12040294
J Clin Oncol. 2001 Nov 15;19(22):4224-37
11709566
J Clin Oncol. 2002 Mar 15;20(6):1456-66
11896092
Cancer. 2002 Jun 15;94(12):3107-14
12115341
Cancer. 2004 Jul 15;101(2):258-63
15241821
Am Surg. 2004 Jul;70(7):565-9
15279176
Strahlenther Onkol. 2003 May;179(5):306-11
12740657
Ann Surg Oncol. 2002 Apr;9(3):243-7
11923130
Asian J Surg. 2004 Oct;27(4):262-7
15564176
Br J Cancer. 2002 Apr 8;86(7):1041-6
11953845
J Clin Oncol. 1998 Jan;16(1):107-14
9440730
Rays. 1997 Jul-Sep;22(3):417-24
9446946
Ann Surg. 2002 Sep;236(3):295-302; discussion 302-3
12192316
Nature. 2000 Aug 17;406(6797):747-52
10963602
Cancer. 2004 May 1;100(9):1814-22
15112261
J Clin Oncol. 2003 Jul 1;21(13):2600-8
12829681
Acta Oncol. 1999;38(5):597-601
10427948
Breast. 2003 Dec;12(6):538-42
14659132
Eur J Cancer. 2002 Nov;38(17):2214-21
12441257
Br J Cancer. 1999 Aug;80(12):1968-73
10471047
J Clin Oncol. 1998 Aug;16(8):2672-85
9704717
Clin Cancer Res. 2000 Dec;6(12):4610-7
11156210
Oncology (Williston Park). 2002 Jul;16(7):871-84, 889; discussion 889-90, 892-4, 897-8
12164555
Clin Breast Cancer. 2002 Oct;3 Suppl 2:S69-74
12435290
Am J Clin Oncol. 2002 Apr;25(2):172-7
11943897
Int J Cancer. 1998 Aug 21;79(4):376-83
9699530
Ann Oncol. 2005 Jan;16(1):56-63
15598939
J Clin Oncol. 2004 Jun 15;22(12):2303-12
15197191
Hum Mutat. 2003 Mar;21(3):292-300
12619115
Breast Cancer. 2002;9(1):8-14
12196715
J Clin Oncol. 1995 Mar;13(3):537-40
7884412
Br J Cancer. 1990 Jun;61(6):877-80
2372489
Bull Cancer. 2002 Aug;89 Spec No:S107-14
12449040
J Surg Oncol. 2002 May;80(1):4-11
11967899
Cancer Res. 1989 Apr 15;49(8):2002-4
2522814
J Clin Oncol. 2004 Jun 15;22(12):2294-302
15197190
World J Surg. 2004 Oct;28(10):1019-24
15573258
J Clin Oncol. 2001 Sep 15;19(18):3828-35
11559720
Hum Pathol. 2004 Jul;35(7):781-4
15257539
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):880-8
12095553
Endocr Relat Cancer. 2003 Mar;10(1):91-8
12653672
Oncologist. 2002;7(3):239-45
12065797
Anticancer Res. 1996 Sep-Oct;16(5B):3105-10
8920776
Crit Rev Oncol Hematol. 2003 Jan;45(1):77-90
12482573
Clin Breast Cancer. 2004 Aug;5(3):198-207
15335452
J Clin Oncol. 1998 Apr;16(4):1633-5
9552079
Ann Surg Oncol. 2004 Sep;11(9):854-60
15313733
J Clin Oncol. 2003 Nov 15;21(22):4165-74
14559892
Lancet. 1998 May 16;351(9114):1451-67
9605801
J Clin Oncol. 2005 Mar 10;23(8):1760-75
15755984
Int J Cancer. 2000 Jan 20;89(1):32-8
10719728
Am J Surg. 1998 Dec;176(6):502-9
9926779
J Natl Cancer Inst Monogr. 2001;(30):96-102
11773300
Br J Cancer. 2003 Feb 10;88(3):406-12
12569384
J Clin Oncol. 2002 Jun 15;20(12):2812-23
12065558
Eur J Cancer. 1995 Nov;31A(12):1969-75
8562150
N Engl J Med. 2002 Dec 19;347(25):1999-2009
12490681
Cancer Res. 1983 Apr;43(4):1488-92
6831397
Cancer. 1979 Feb;43(2):451-8
421172
Ann Oncol. 1999 Jan;10(1):47-52
10076721
J Cancer Res Clin Oncol. 2004 May;130(5):273-8
14986112
Eur J Cancer. 2004 Feb;40(3):342-51
14746851
Am J Surg. 2001 Oct;182(4):407-10
11720681
Lancet. 1998 Sep 19;352(9132):930-42
9752815